Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing next-generation precision medicines targeting FGFR biology. The news flow around TYRA, as reflected in its recent press releases, centers on clinical trial progress, scientific presentations, regulatory designations and corporate developments related to its FGFR-focused pipeline.
Investors and followers of TYRA news can expect updates on dabogratinib (formerly TYRA-300), the company’s lead oral FGFR3-selective inhibitor. Recent announcements include dosing the first patient in the SURF302 Phase 2 study for FGFR3-altered intermediate risk non-muscle invasive bladder cancer, dosing the first child in the BEACH301 Phase 2 study for pediatric achondroplasia, and plans to expand development into low-grade upper tract urothelial carcinoma through the SURF303 study. Tyra also reports interim proof-of-concept results in metastatic urothelial carcinoma and regulatory designations such as Orphan Drug Designation and Rare Pediatric Disease Designation for dabogratinib in achondroplasia.
News coverage further highlights progress in early-stage oncology programs TYRA-200 and TYRA-430, including enrollment and dosing in the SURF201 and SURF431 Phase 1 studies for intrahepatic cholangiocarcinoma, hepatocellular carcinoma and other FGFR-driven tumors. Tyra’s communications also describe scientific visibility events, such as a late-breaking poster on TYRA-300 preclinical data at ENDO 2025 and fireside chats or presentations at healthcare and biotechnology investor conferences.
In addition, Tyra Biosciences issues quarterly financial results press releases and Form 8-K filings that summarize research and development spending, cash runway expectations and key clinical milestones. Corporate news has included strengthening the leadership team with appointments in operations and regulatory affairs. For readers tracking TYRA, this news stream provides ongoing insight into the company’s clinical development timelines, scientific activities and corporate priorities in FGFR-targeted precision medicine.
Tyra Biosciences announced promising preclinical results for TYRA-300, an oral FGFR3 selective inhibitor, in treating hypochondroplasia (HCH).
Presented at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference, the data showed TYRA-300 increased long bone lengths by up to 5.03% and skull size by 5.88% in mouse models, compared to vehicle-treated mice. The results support the potential of TYRA-300 as a best-in-class agent for FGFR3-related skeletal dysplasias like HCH.
The company plans to submit an Investigational New Drug (IND) application for achondroplasia (ACH) in the second half of 2024, aiming for a Phase 2 study in pediatric ACH.
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology firm specializing in precision medicines for FGFR biology, will participate in several investor conferences. On May 28-29, 2024, CEO Todd Harris will join a fireside chat at TD Cowen's Oncology Innovation Summit. The company will engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 5-6, 2024. Additionally, Harris will present on June 12, 2024, at the Goldman Sachs Global Healthcare Conference, with further investor meetings scheduled. Webcasts of these presentations will be available on Tyra's Investor page.
Tyra Biosciences, a clinical-stage biotechnology company, reported financial results for Q1 2024, with $382.5 million in cash and marketable securities. Recent highlights include progress on TYRA-300 in oncology and achondroplasia, new board appointments, and completion of a $200M private placement financing. The company continues to advance its pipeline and expects to report SURF301 Phase 1 initial results in 2H24.
Tyra Biosciences, a clinical-stage biotech company, appointed Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as independent directors, replacing Isan Chen, M.D. Both new directors bring extensive expertise in FGFR3 biology and oncology. Dr. Moran has a background in clinical trials and product development, while Dr. Rothenberg has experience in clinical care and drug development. The changes aim to advance the company's precision medicine candidates, particularly TYRA-300 for skeletal dysplasias and oncology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.